Explore Xeris Biopharma's revenue growth, promising pipeline, & thriving products. Learn about their strong outlook & ...

The first time Dr. Fajgenbaum repurposed a drug, it was in an attempt to save his own life. At 25, while in medical school, ...

since up to this time there has been a rather clear separation between the agents that benefit each syndrome. Heretofore, what was effective therapy for one type of periodic paralysis has ...

Xeris Biopharma Holdings has received regulatory approval for a new use of its Gvoke liquid glucagon in gastrointestinal ...

Xeris Biopharma Holdings, Inc. , a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, ...

Xeris has three commercially available products: Recorlev®, for the treatment of endogenous Cushing’s syndrome ... a proven therapy for primary periodic paralysis. Xeris also has a pipeline ...

Individuals with high PLMs had significantly higher Fazekas and ARWMC total scores than those with a lower PLM index.

Anne Marie Hochhalter died Feb. 16 of sepsis — an extreme reaction to infection — and complications from her paralysis were a “significant contributing factor” in her death, the Jefferson ...

Low doses of antibiotic work just as well as higher ones to treat rare type of chronic hair loss, study finds Small amounts of a common antibiotic and anti-inflammatory drug can curb symptoms ...